Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -8.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 2.79 | 3.07 | 3.22 | 1.87 | 2.92 | 2.45 | 1.80 | 2.35 | 2.64 | 1.64 | 2.82 | 2.36 | 1.40 | 1.32 | 1.27 | 1.06 | 0.59 | 0.75 | 0.83 | 2.12 | 2.80 |
| — | +25.4% | +78.3% | -20.3% | +10.6% | +48.8% | -36.0% | -0.6% | +88.0% | +24.8% | +122.4% | +122.0% | +138.1% | +76.5% | +52.3% | -49.9% | -78.9% | -70.3% | -74.4% | -46.0% | -32.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.3% | -10.4% | -8.9% | -7.7% | -8.9% | -13.4% | -13.0% | -14.0% | -12.0% | -10.1% | -9.0% | -12.0% | -9.9% | -9.7% | -11.3% | -9.5% | -11.0% | -8.3% | -8.8% | -8.1% | -6.7% |
| — | +22.1% | +31.1% | +45.1% | +25.7% | -32.0% | -43.3% | -16.9% | -21.5% | -4.1% | +19.7% | -26.0% | +10.2% | -17.5% | -27.9% | -18.2% | -64.0% | -5.3% | -50.9% | +32.3% | +50.2% | |
| ROA | -37.8% | -9.9% | -8.4% | -7.2% | -8.4% | -12.3% | -11.6% | -12.6% | -11.0% | -9.4% | -8.3% | -10.7% | -9.0% | -8.9% | -10.0% | -8.5% | -10.0% | -7.6% | -8.1% | -7.4% | -6.3% |
| — | +20.0% | +27.3% | +42.5% | +23.5% | -31.1% | -40.6% | -17.7% | -21.7% | -6.3% | +17.7% | -25.4% | +9.8% | -16.6% | -24.4% | -14.9% | -57.7% | +0.3% | -42.5% | +35.5% | +51.3% | |
| ROIC | -39.9% | -9.6% | -8.3% | -7.3% | -9.0% | -13.8% | -13.6% | -14.1% | -11.8% | -10.2% | -8.9% | -10.8% | -11.0% | -11.9% | -12.3% | -9.3% | -10.2% | -9.3% | -18.2% | -33.8% | -19.5% |
| — | +30.5% | +38.7% | +48.4% | +23.6% | -35.4% | -52.1% | -30.4% | -7.2% | +14.6% | +27.0% | -16.3% | -7.9% | -27.9% | +32.7% | +72.5% | +47.8% | +22.2% | -182.7% | -166.1% | +38.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.01 | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 | 0.01 | 0.01 | 0.01 | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -13.7% | -45.8% | +129.6% | -28.8% | +10.3% | +73.2% | -71.3% | +3.3% | -8.9% | -36.1% | -16.2% | -10.1% | -8.8% | +65.3% | +671.1% | +99.0% | +76.6% | +19.0% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.13 | 13.19 | 16.33 | 14.13 | 14.65 | 16.13 | 12.00 | 10.56 | 13.15 | 15.08 | 21.31 | 10.39 | 12.26 | 18.46 | 12.99 | 13.68 | 14.96 | 18.72 | 20.23 | 15.87 | 24.60 |
| — | -18.2% | +36.1% | +33.9% | +11.4% | +7.0% | -43.7% | +1.6% | +7.3% | -18.3% | +64.0% | -24.0% | -18.0% | -1.4% | -35.8% | -13.8% | -39.2% | -30.0% | -44.6% | -51.8% | -9.8% | |
| Quick Ratio | 14.13 | 13.19 | 16.33 | 14.13 | 14.65 | 16.13 | 12.00 | 10.56 | 13.15 | 15.08 | 21.31 | 10.39 | 12.26 | 18.46 | 12.99 | 13.68 | 14.96 | 18.72 | 20.23 | 15.87 | 24.60 |
| — | -18.2% | +36.1% | +33.9% | +11.4% | +7.0% | -43.7% | +1.6% | +7.3% | -18.3% | +64.0% | -24.0% | -18.0% | -1.4% | -35.8% | -13.8% | -39.2% | -30.0% | -44.6% | -51.8% | -9.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | -14.26 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ORIC stock.
ORIC Pharmaceuticals, Inc.'s current P/E is -8.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ORIC Pharmaceuticals, Inc.'s business trajectory between earnings reports.